Table 3 Minimal inhibition concentration (µg/ml) of compound 9
From: A comprehensive review on biological activities of oxazole derivatives
Compd. | MIC (µg/ml) | |||
|---|---|---|---|---|
S. aureus | E. coli | |||
FDA 209P | KMP 9 | NIHJ JC-2 | W3110 ∆acrA | |
9 | 2 | 2 | 64 | 4 |
Sparfloxacin | 0.125 | 128 | 0.032 | 0.004 |
Novobiocin | 0.25 | 0.25 | 64 | 0.5 |